Literature DB >> 2973527

Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human colorectal carcinoma cell lines.

J G Park1, J M Collins, A F Gazdar, C J Allegra, S M Steinberg, R F Greene, B S Kramer.   

Abstract

Reduced folates have been shown to increase the cytotoxicity of 5-fluorouracil (5-FU) by stabilizing the 5-fluoro-2'-deoxyuridine-5'-monophosphate-thymidylate synthase complex, thus increasing the block in the DNA synthetic pathway. Using an in vitro colorimetric [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] cytotoxicity assay, we tested the effects of 5-FU and 5-fluoro-2'-deoxyuridine (FdUrd) with and without leucovorin (LV) on a panel of 11 human colorectal carcinoma cell lines. The effect of LV on 5-FU and FdUrd was quantitatively similar. A clinically achievable level of LV (20 microM) increased the cytotoxicity in all three replicate experiments in 10 of the 11 cell lines (P less than .05, binomial test). LV alone at a concentration of 20 microM had no effect on cell survival. In three cell lines, 50% inhibition of growth occurred at a clinically achievable area under the curve of 5-FU alone. With the addition of LV, one additional cell line showed 50% growth inhibition at a clinically achievable level of 5-FU. Hence large clinical trials may be necessary to detect a significant improvement in survival as a result of adding LV to the fluorinated pyrimidines.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2973527     DOI: 10.1093/jnci/80.19.1560

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  15 in total

1.  In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines.

Authors:  Y Sugimoto; Y Ohe; K Nishio; T Ohmori; Y Fujiwara; N Saijo
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  Transarterial approaches to primary and secondary hepatic malignancies.

Authors:  Ali Habib; Kush Desai; Ryan Hickey; Bartley Thornburg; Robert Lewandowski; Riad Salem
Journal:  Nat Rev Clin Oncol       Date:  2015-05-19       Impact factor: 66.675

3.  Extreme Prostate-Specific Antigen Response to Infusional 5-Flourouracil in Castrate-Resistant Prostate Cancer.

Authors:  Charlotte Manogue; Elisa Ledet; A Kumar Guddati; Brian Lewis; Oliver Sartor
Journal:  Oncologist       Date:  2017-12-19

Review 4.  Transcatheter intraarterial therapies: rationale and overview.

Authors:  Robert J Lewandowski; Jean-Francois Geschwind; Eleni Liapi; Riad Salem
Journal:  Radiology       Date:  2011-06       Impact factor: 11.105

5.  5FU resistance caused by reduced fluoro-deoxyuridine monophosphate and its reversal using deoxyuridine.

Authors:  Ryutaro Mori; Manabu Futamura; Toshiyuki Tanahashi; Yoshihiro Tanaka; Nobuhisha Matsuhashi; Kazuya Yamaguchi; Kazuhiro Yoshida
Journal:  Oncol Lett       Date:  2017-06-30       Impact factor: 2.967

6.  Biology of SNU cell lines.

Authors:  Ja-Lok Ku; Jae-Gahb Park
Journal:  Cancer Res Treat       Date:  2005-02-28       Impact factor: 4.679

7.  5-Fluorouracil (5FU) with or without folinic acid (LV) in human colorectal cancer? Multivariate meta-analysis of the literature.

Authors:  D Brohée
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

Review 8.  New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: Thymidylate synthase.

Authors:  C L van der Wilt; G J Peters
Journal:  Pharm World Sci       Date:  1994-04-15

Review 9.  Tropomyosin-related kinase B/brain derived-neurotrophic factor signaling pathway as a potential therapeutic target for colorectal cancer.

Authors:  Hussein Akil; Aurélie Perraud; Marie-Odile Jauberteau; Muriel Mathonnet
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

10.  Phase I and pharmacologic evaluation of intraperitoneal 5-fluoro-2'-deoxyuridine.

Authors:  F M Muggia; K K Chan; C Russell; N Colombo; J L Speyer; K Sehgal; S Jeffers; J Sorich; L Leichman; U Beller
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.